Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

6 terminated/withdrawn out of 10 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
8(80.0%)
Early Phase 1
1(10.0%)
Phase 1
1(10.0%)
10Total
Phase 2(8)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT04858425Phase 2Terminated

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

Role: lead

NCT05719311Phase 2Completed

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

Role: lead

NCT04243551Phase 2Terminated

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

Role: lead

NCT04839575Phase 2Terminated

Study of Latiglutenase in T1D/CD Patients

Role: lead

NCT03011931Early Phase 1Completed

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

Role: lead

NCT03521232Phase 1Terminated

A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis

Role: lead

NCT04375878Phase 2Completed

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Role: lead

NCT03746483Phase 2Completed

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Role: lead

NCT04542434Phase 2Withdrawn

Niclosamide in COVID-19

Role: lead

NCT04436458Phase 2Withdrawn

Niclosamide In Moderate COVID-19

Role: lead

All 10 trials loaded